A Phase 2 interventional study of Benralizumab 2 mg and Benralizumab 20 mg in Asthma, sponsored by MedImmune LLC. Completed at 79 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-11-17.
Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.
Among the 39 studies testing benralizumab in Asthma, this one is the 4th largest by enrollment, is the only one that started in 2010, is one of 7 in phase 2, and was the 5th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
University of California, San Diego · Sites in United States
Ages 18–75
Endeavor Health · Sites in United States
Ages 18+
By country, each count listing its studies:
benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 964 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 128 across the 39 interventional studies. Of the 31 that completed or were terminated, 24 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under MedImmune LLC, one of the names counted as AstraZeneca. Under that name alone:
MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 35th largest by enrollment of the 248 interventional ones that give a count, is one of 15 that started in 2010, is one of 50 in phase 2, and was the 149th registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing benralizumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
| NCT07654842Endeavor HealthFasenra: An Asthma Study | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies testing benralizumab in Asthma, from their registry updates:
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the effect of multiple-dose subcutaneous administrations of MEDI-563 on adults with uncontrolled asthma.
This is a Phase 2b, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of multiple-dose (7 doses) subcutaneous administration of benralizumab (MEDI-563) in adult subjects with uncontrolled asthma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
EOS+ (defined as ELEN Index \[proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent\] positive and/or FeNO \[fraction of exhaled nitric oxide\] greater than or equal to \[\>=\] 50 parts per billion \[ppb\]) participants received matching placebo injections subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
Other: Placebo
EOS+ participants received single benralizumab 2 milligram (mg) injection subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
Biological: Benralizumab 2 mg
EOS+ participants received single benralizumab 20 mg injection subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
Biological: Benralizumab 20 mg
EOS+ participants received benralizumab 50 mg as two injections subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
Biological: Benralizumab 100 mg
EOS- (defined as ELEN Index negative and FeNO \<50 ppb) participants received matching placebo subcutaneous every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
Other: Placebo
EOS- participants received benralizumab 50 mg as two injections subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
Biological: Benralizumab 100 mg
EOS+ participants received single benralizumab 2 milligram (mg) injection followed by a single placebo injection subcutaneously.
Also known as: MEDI-563
EOS+ participants received single benralizumab 20 mg injection followed by a single placebo injection subcutaneously.
Also known as: MEDI-563
EOS+ and EOS- participants received two benralizumab 50 mg injections subcutaneously.
Also known as: MEDI-563
EOS+ and EOS- participants received two placebo injections subcutaneously.
Annual Asthma Exacerbation Rate (AER) for Eosinophilic Phenotype (EOS+) Participants
The annual asthma exacerbation rate (AER) was calculated as the total number of observed exacerbations in each group up to week 52, divided by total duration of person-year follow-up in each group. An asthma exacerbation is defined as a progressive increase of asthma symptoms (cough, wheeze, chest tightness, and/or shortness of breath) that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 days as prescribed or administered by the investigator or healthcare provider; or 2) participant initiation of systemic corticosteroids (tablets, suspension or injection) for a duration of at least 3 days as outlined in the Asthma Action Plan provided to the participant by the investigator on Day 1.
Time frame: Week 1 up to Week 52
Dose Response in EOS+ Participants
Time frame: Baseline up to Week 66
Minimum Observed Serum Trough Concentration for Benralizumab at Steady-State (Ctrough, ss)
Time frame: Pre-dose (0 hour), Post-dose on Day 1, 6, Week 4, 16, 24, 32, 40, and 52
Dose-Normalized Minimum Observed Serum Trough Concentration for Benralizumab at Steady-State (Ctrough, ssD)
Time frame: Pre-dose (0 hour), Post-dose on Day 1, 6, Week 4, 16, 24, 32, 40, and 52
Percentage of Participants With Anti-Drug Antibodies (ADA) to Benralizumab in Eosinophilic Phenotype (EOS+) Participants
Immunogenicity assessment included determination of anti-drug (benralizumab) antibodies in serum samples. ADA positive was defined as a titer \>=50 at any point in the study. It was observed at baseline and any visit during the study.
Time frame: Baseline up to Week 92
Change From Baseline in Asthma Control Questionnaire (6-items) (ACQ-6) Score at Week 52
Asthma Control Questionnaire (ACQ) is a participant-reported questionnaire to assess the asthma control with 6 items assessing night-time waking, symptoms on waking, activity limitation, shortness of breath, wheeze, and rescue short-acting beta agonist use. Each item was rated on a 7-point Likert scale ranging from 0 (no impairment) to 6 (maximum impairment). Overall ACQ score was the mean of the 6 item scores with a score range of 0 (well controlled) to 6 (extremely poor controlled). Data collected on Day 1 prior to dosing was considered as baseline. Results were reported for overall ACQ score. ACQ-6 score was summarized together for all participants.
Time frame: Baseline up to Week 52
Change From Baseline in Mean Total Nasal Symptoms Score (TNSS) at Week 52
Total Nasal Symptoms Score (TNSS) is a 3-item questionnaire, the sum of nasal symptoms, namely, nasal obstruction (rhinorrhea), nasal congestion, and nasal itching/sneezing. Each symptom was rated on a scale from 0-3, with 0 representing no symptoms, 1 mild, 2 moderate, and 3 severe symptoms. TNSS score was a summation of the 3 individual nasal symptom. TNSS score could range from 0 to 9 where higher score indicates worsening. Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.
Time frame: Baseline up to Week 52
Change From Baseline in Mean Asthma Symptom Diary Score at Week 51-52
Asthma Symptom Diary included 7 questions about the participant symptom and the overall impact of treatment on the disease during the study period. Mean scores of the 7 questions were calculated to identify asthma symptom-free days. Asthma Symptom Diary Scores were analyzed on a bi-weekly basis and compared to baseline scores. Overall symptom score=(daytime frequency score + daytime severity score + nighttime severity score)/3, where total score ranges from 0 to 9. Higher score represents worsening. Mean asthma symptom diary score were summarized together for all participants. Mean asthma symptom diary score were summarized together for all participants. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.
Time frame: Baseline up to Week 51-52
Change From Baseline in Rescue Medication Use at Week 51-52
Participants were provided inhalers of the same dose (medium- or high-dose) inhaled corticosteroid (ICS) plus long-acting beta antagonist (LABA) combination product as baseline prophylactic medication and continued with same dose throughout the study. Rescue medications such as short-term beta2 agonists were used as first-line treatment for worsening asthma symptoms. Investigator prescribed additional short term asthma controller medications included additional ICS, theophylline, inhaled cromones or antimuscarinics; if asthma symptoms remained mild but not resolved. If asthma symptoms worsened, participants received an oral corticosteroid burst. All rescue medications use with prophylactic medication (+ prophylactic) and without prophylactic medication (- prophylactic) was recorded in asthma symptom dairy by participant. Rescue medication use was analyzed on a bi-weekly basis and compared to baseline scores.
Time frame: Baseline up to Week 51-52
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 52
FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.
Time frame: Baseline and Week 52
Change From Baseline in Mean Forced Vital Capacity (FVC) at Week 52
Forced Vital Capacity (FVC) was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible.
Time frame: Baseline and Week 52
Change From Baseline in Peak Expiratory Flow (PEF) at Week 52
The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed while sitting or standing prior to using any medication (if needed) for asthma. Home PEF was determined separately for morning and evening, and were averaged for each participant. Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.
Time frame: Baseline and Week 52
Change From Baseline in Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ[S]) Score at Week 52
AQLQ: a 32-item questionnaire evaluating quality of life of participants with asthma including 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants were asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score was calculated as the mean response to all questions. The 4 domain scores were the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment). The AQLQ(S) responses were categorized as improvement (defined as change from baseline \>=0.5), no change (defined as change from baseline \>= -0.5 to less than \[\<\] 0.5), and worse (defined as change from baseline \< -0.5). Data was summarized by each treatment group.
Time frame: Baseline and Week 52
Change From Baseline in European Quality of Life - 5 Dimensions (EQ-5D) Health State Evaluation at Week 52
The utility-based EQ-5D questionnaire comprises of two parts and provides a generic measure of health for clinical and economic appraisal. The health state valuation was the summary score of mobility, self-care, usual activities, pain/discomfort and anxiety/depression on a 3 category scale (no problem, moderate problem, severe problems). Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.
Time frame: Baseline and Week 52
Change From Baseline in EQ-5D Visual Analog Scale (VAS) at Week 52
The utility-based EQ-5D questionnaire comprises of two parts and provides a generic measure of health for clinical and economic appraisal. The EQ-5D VAS was measured from 0 (worst imaginable health state) to 100 (best imaginable health state). Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.
Time frame: Baseline and Week 52
Change From Baseline in Percentage of Nocturnal Awakening-Free Nights at Week 51-52
Percentage of nocturnal awakening-free nights were analyzed on a bi-weekly basis and compared to baseline scores. Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.
Time frame: Baseline up to Week 51-52
Change From Baseline in Mean Fraction Exhaled Nitric Oxide (FeNO) at Week 52
Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.
Time frame: Baseline up to Week 52
| Milestone | Eosinophilic Phenotype (EOS+) Placebo | EOS+ Benralizumab, 2 mg | EOS+ Benralizumab, 20 mg | EOS+ Benralizumab, 100 mg | Non-eosinophil Phenotype (EOS-) Placebo | EOS- Benralizumab, 100 mg |
|---|---|---|---|---|---|---|
| Started | 80 | 81 | 81 | 82 | 142 | 140 |
| Completed | 69 | 73 | 70 | 69 | 129 | 125 |
| Not completed | 11 | 8 | 11 | 13 | 13 | 15 |
| Withdrew: Lost to follow-up | 4 | 2 | 3 | 1 | 1 | 2 |
| Withdrew: Unplanned surgery | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Did not meet entry acq-6 criteria | 0 | 0 | 1 | 0 | 1 | 1 |
| Withdrew: Incorrect enrollment/randomization | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Subject traveled to argentina by 1 year | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Subject moved out of state/area | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Strongyloides stercoralis antibodies + | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Personal problems | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Unable to continue visits | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Serious adverse event | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lack of compliance | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 5 | 4 | 8 | 10 | 9 |
The annual asthma exacerbation rate (AER) was calculated as the total number of observed exacerbations in each group up to week 52, divided by total duration of person-year follow-up in each group. An asthma exacerbation is defined as a progressive increase of asthma symptoms (cough, wheeze, chest tightness, and/or shortness of breath) that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 days as prescribed or administered by the investigator or healthcare provider; or 2) participant initiation of systemic corticosteroids (tablets, suspension or injection) for a duration of at least 3 days as outlined in the Asthma Action Plan provided to the participant by the investigator on Day 1.
| AER events/person-year | Eosinophilic Phenotype (EOS+) Placebo | EOS+ Benralizumab, 2 mg | EOS+ Benralizumab, 20 mg | EOS+ Benralizumab, 100 mg |
|---|---|---|---|---|
| Annual Asthma Exacerbation Rate (AER) for Eosinophilic Phenotype (EOS+) Participants | 0.57 | 0.65 | 0.37 | 0.34 |
No measurements were reported for this outcome.
| microgram per milliliter | EOS+ Benralizumab, 2 mg | EOS+ Benralizumab, 20 mg | Benralizumab, 100 mg |
|---|---|---|---|
| Minimum Observed Serum Trough Concentration for Benralizumab at Steady-State (Ctrough, ss) | 34.7 ± 131 | 182 ± 180 | 869 ± 665 |
| microgram per milliliter | EOS+ Benralizumab, 2 mg | EOS+ Benralizumab, 20 mg | Benralizumab, 100 mg |
|---|---|---|---|
| Dose-Normalized Minimum Observed Serum Trough Concentration for Benralizumab at Steady-State (Ctrough, ssD) | 17.3 ± 65.3 | 9.10 ± 9.02 | 8.69 ± 6.65 |
Immunogenicity assessment included determination of anti-drug (benralizumab) antibodies in serum samples. ADA positive was defined as a titer \>=50 at any point in the study. It was observed at baseline and any visit during the study.
| percentage of participants | EOS+ Placebo | EOS+ Benralizumab, 2 mg | EOS+ Benralizumab, 20 mg | EOS+ Benralizumab, 100 mg |
|---|---|---|---|---|
| Percentage of Participants With Anti-Drug Antibodies (ADA) to Benralizumab in Eosinophilic Phenotype (EOS+) Participants | 3.8 | 42.0 | 30.9 | 25.6 |
Asthma Control Questionnaire (ACQ) is a participant-reported questionnaire to assess the asthma control with 6 items assessing night-time waking, symptoms on waking, activity limitation, shortness of breath, wheeze, and rescue short-acting beta agonist use. Each item was rated on a 7-point Likert scale ranging from 0 (no impairment) to 6 (maximum impairment). Overall ACQ score was the mean of the 6 item scores with a score range of 0 (well controlled) to 6 (extremely poor controlled). Data collected on Day 1 prior to dosing was considered as baseline. Results were reported for overall ACQ score. ACQ-6 score was summarized together for all participants.
| units on a scale | EOS+ Placebo | EOS+ Benralizumab, 2 mg | EOS+ Benralizumab, 20 mg | EOS+ Benralizumab, 100 mg | EOS- Placebo | EOS- Benralizumab, 100 mg |
|---|---|---|---|---|---|---|
| Baseline (n=80,80,80,82,142,140) | 2.7479 ± 0.9762 | 2.6479 ± 0.9908 | 2.4750 ± 0.9106 | 2.5346 ± 0.9728 | 2.4742 ± 0.8408 | 2.6381 ± 0.8330 |
| Change at Week 52 (n=34,42,40,39,64,73) | -0.8922 ± 1.1969 | -1.1032 ± 1.1207 | -1.2500 ± 1.2247 | -1.1239 ± 1.2852 | -0.8418 ± 1.1343 | -1.1295 ± 1.1301 |
Total Nasal Symptoms Score (TNSS) is a 3-item questionnaire, the sum of nasal symptoms, namely, nasal obstruction (rhinorrhea), nasal congestion, and nasal itching/sneezing. Each symptom was rated on a scale from 0-3, with 0 representing no symptoms, 1 mild, 2 moderate, and 3 severe symptoms. TNSS score was a summation of the 3 individual nasal symptom. TNSS score could range from 0 to 9 where higher score indicates worsening. Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.
| units on a scale | Placebo | EOS+ Benralizumab, 2 mg | EOS+ Benralizumab, 20 mg | Benralizumab (100 mg) |
|---|---|---|---|---|
| Baseline (n=71,27,25,81) | 4.3 ± 2.0 | 4.8 ± 2.0 | 5.3 ± 1.8 | 4.4 ± 2.1 |
| Change at Week 52 (n=89,39,39,106) | -0.4 ± 2.90 | -0.8 ± 2.01 | -1.0 ± 2.96 | -0.8 ± 2.24 |
Asthma Symptom Diary included 7 questions about the participant symptom and the overall impact of treatment on the disease during the study period. Mean scores of the 7 questions were calculated to identify asthma symptom-free days. Asthma Symptom Diary Scores were analyzed on a bi-weekly basis and compared to baseline scores. Overall symptom score=(daytime frequency score + daytime severity score + nighttime severity score)/3, where total score ranges from 0 to 9. Higher score represents worsening. Mean asthma symptom diary score were summarized together for all participants. Mean asthma symptom diary score were summarized together for all participants. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.
| units on a scale | Placebo | EOS+ Benralizumab, 2 mg | EOS+ Benralizumab, 20 mg | Benralizumab (100 mg) |
|---|---|---|---|---|
| Baseline (n=204,72,74,210) | 1.58 ± 0.60 | 1.65 ± 0.65 | 1.60 ± 0.61 | 1.60 ± 0.62 |
| Change at Week 51-52 (n=111,36,39,111) | -0.37 ± 0.61 | -0.56 ± 0.76 | -0.56 ± 0.69 | -0.53 ± 0.67 |
Participants were provided inhalers of the same dose (medium- or high-dose) inhaled corticosteroid (ICS) plus long-acting beta antagonist (LABA) combination product as baseline prophylactic medication and continued with same dose throughout the study. Rescue medications such as short-term beta2 agonists were used as first-line treatment for worsening asthma symptoms. Investigator prescribed additional short term asthma controller medications included additional ICS, theophylline, inhaled cromones or antimuscarinics; if asthma symptoms remained mild but not resolved. If asthma symptoms worsened, participants received an oral corticosteroid burst. All rescue medications use with prophylactic medication (+ prophylactic) and without prophylactic medication (- prophylactic) was recorded in asthma symptom dairy by participant. Rescue medication use was analyzed on a bi-weekly basis and compared to baseline scores.
| rescue medication per 2 weeks | Placebo | EOS+ Benralizumab, 2 mg | EOS+ Benralizumab, 20 mg | Benralizumab (100 mg) |
|---|---|---|---|---|
| Baseline without prophylactic (n=204,72,74,210) | 3.09 ± 2.55 | 3.57 ± 3.67 | 3.82 ± 4.34 | 3.16 ± 2.82 |
| Baseline with prophylactic (n=204,72,74,210) | 4.07 ± 3.34 | 4.71 ± 5.56 | 5.24 ± 6.40 | 4.22 ± 3.90 |
| Change Week 51-52 -prophylactic(n=111,36,39,111) | -1.2540 ± 2.4571 | -1.4116 ± 2.8722 | -1.8804 ± 5.3129 | -1.1589 ± 2.0086 |
| Change Week 51-52 +prophylactic(n=111,36,39,111) | -1.6855 ± 3.2875 | -1.6810 ± 4.2247 | -2.5118 ± 7.6814 | -1.4693 ± 2.5603 |
FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.
| liters | Placebo | EOS+ Benralizumab, 2 mg | EOS+ Benralizumab, 20 mg | Benralizumab (100 mg) |
|---|---|---|---|---|
| Baseline (n=215,80,81,218) | 2.033 ± 0.669 | 1.978 ± 0.701 | 2.080 ± 0.751 | 2.012 ± 0.672 |
| Change at Week 52 (n=150,51,58,160) | 0.0098 ± 0.3615 | 0.1631 ± 0.4691 | 0.1847 ± 0.5234 | 0.0998 ± 0.3541 |
Forced Vital Capacity (FVC) was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible.
| liters | EOS+ Placebo | EOS+ Benralizumab, 2 mg | EOS+ Benralizumab, 20 mg | EOS+ Benralizumab, 100 mg | EOS- Placebo | EOS- Benralizumab, 100 mg |
|---|---|---|---|---|---|---|
| Baseline (n=80,80,81,82,135,136) | 3.282 ± 1.030 | 3.069 ± 0.957 | 3.285 ± 1.028 | 3.110 ± 0.851 | 3.043 ± 0.864 | 3.126 ± 0.981 |
| Change at Week 52 (n=51,51,58,59,99,101) | 0.029 ± 0.514 | 0.129 ± 0.565 | 0.190 ± 0.586 | 0.166 ± 0.445 | -0.030 ± 0.426 | 0.056 ± 0.371 |
The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed while sitting or standing prior to using any medication (if needed) for asthma. Home PEF was determined separately for morning and evening, and were averaged for each participant. Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.
| liters per minute | Placebo | EOS+ Benralizumab, 2 mg | EOS+ Benralizumab, 20 mg | Benralizumab (100 mg) |
|---|---|---|---|---|
| Baseline (n=215,80,81,218) | 319.3 ± 104.7 | 325.5 ± 101.6 | 323.1 ± 100.8 | 323.8 ± 101.7 |
| Change at Week 52 (n=150,51,58,160) | 13.0 ± 64.6 | 29.0 ± 64.1 | 45.9 ± 95.5 | 26.6 ± 66.3 |
AQLQ: a 32-item questionnaire evaluating quality of life of participants with asthma including 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants were asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score was calculated as the mean response to all questions. The 4 domain scores were the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment). The AQLQ(S) responses were categorized as improvement (defined as change from baseline \>=0.5), no change (defined as change from baseline \>= -0.5 to less than \[\<\] 0.5), and worse (defined as change from baseline \< -0.5). Data was summarized by each treatment group.
| units on a scale | Placebo | EOS+ Benralizumab, 2 mg | EOS+ Benralizumab, 20 mg | Benralizumab (100 mg) |
|---|---|---|---|---|
| Baseline (n=214,78,80,217) | 3.72 ± 1.04 | 3.72 ± 1.17 | 3.79 ± 1.06 | 3.72 ± 1.01 |
| Change at Week 52 (n=88,39,38,105) | 0.9634 ± 1.3342 | 1.2612 ± 1.2082 | 1.4474 ± 1.4262 | 1.1223 ± 1.2636 |
The utility-based EQ-5D questionnaire comprises of two parts and provides a generic measure of health for clinical and economic appraisal. The health state valuation was the summary score of mobility, self-care, usual activities, pain/discomfort and anxiety/depression on a 3 category scale (no problem, moderate problem, severe problems). Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.
| units on a scale | Placebo | EOS+ Benralizumab, 2 mg | EOS+ Benralizumab, 20 mg | Benralizumab (100 mg) |
|---|---|---|---|---|
| Baseline (n=213,79,74,209) | 0.7629 ± 0.2153 | 0.7418 ± 0.2376 | 0.7877 ± 0.1878 | 0.7679 ± 0.1623 |
| Change at Week 52 (n=148,58,53,161) | 0.0853 ± 0.2096 | 0.0822 ± 0.3137 | 0.1223 ± 0.2132 | 0.0824 ± 0.2179 |
The utility-based EQ-5D questionnaire comprises of two parts and provides a generic measure of health for clinical and economic appraisal. The EQ-5D VAS was measured from 0 (worst imaginable health state) to 100 (best imaginable health state). Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.
| units on a scale | Placebo | EOS+ Benralizumab, 2 mg | EOS+ Benralizumab, 20 mg | Benralizumab (100 mg) |
|---|---|---|---|---|
| Baseline (n=213,79,74,208) | 65.0798 ± 17.8903 | 65.4937 ± 18.5063 | 64.3378 ± 18.1427 | 64.6250 ± 19.7778 |
| Change at Week 52 (n=148,58,53,161) | 12.8041 ± 19.1036 | 12.5517 ± 20.8008 | 15.4906 ± 21.7297 | 13.7391 ± 20.5139 |
Percentage of nocturnal awakening-free nights were analyzed on a bi-weekly basis and compared to baseline scores. Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.
| percent nocturnal awakening-free nights | Placebo | EOS+ Benralizumab, 2 mg | EOS+ Benralizumab, 20 mg | Benralizumab (100 mg) |
|---|---|---|---|---|
| Baseline (n=204,72,74,210) | 52.05 ± 36.96 | 45.07 ± 40.04 | 51.57 ± 39.72 | 50.92 ± 37.72 |
| Change at Week 51-52 (n=111,36,39,111) | 19.7595 ± 39.1388 | 27.1749 ± 41.7342 | 29.6181 ± 38.4315 | 23.3054 ± 36.2761 |
Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.
| parts per billion | Placebo | EOS+ Benralizumab, 2 mg | EOS+ Benralizumab, 20 mg | Benralizumab (100 mg) |
|---|---|---|---|---|
| Baseline (n=222,81,81,222) | 26.88 ± 23.57 | 39.52 ± 32.67 | 40.79 ± 31.03 | 26.68 ± 23.10 |
| Change at Week 52 (n=148,57,56,157) | 1.2523 ± 16.0200 | -3.2222 ± 33.2543 | -6.1905 ± 30.1103 | 1.4384 ± 28.9090 |
Collected over From initiation of investigational product administration up to Week 92. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EOS POS Placebo | — | 7/80 (8.8%) | 44/80 (55%) |
| EOS POS Benralizumab 2 mg | — | 10/81 (12.3%) | 54/81 (66.7%) |
| EOS POS Benralizumab 20 mg | — | 6/81 (7.4%) | 57/81 (70.4%) |
| EOS POS Benralizumab 100 mg | — | 6/82 (7.3%) | 68/82 (82.9%) |
| EOS NEG Placebo | — | 16/141 (11.3%) | 94/141 (66.7%) |
| EOS NEG Benralizumab 100 mg | — | 18/141 (12.8%) | 93/141 (66%) |
| Event | EOS POS Placebo | EOS POS Benralizumab 2 mg | EOS POS Benralizumab 20 mg | EOS POS Benralizumab 100 mg | EOS NEG Placebo | EOS NEG Benralizumab 100 mg |
|---|---|---|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 2/80 | 2/81 | 0/81 | 2/82 | 8/141 | 5/141 |
| Myocardial ischaemiaCardiac disorders | 0/80 | 0/81 | 2/81 | 0/82 | 0/141 | 0/141 |
| Back painMusculoskeletal and connective tissue disorders | 0/80 | 2/81 | 0/81 | 0/82 | 0/141 | 0/141 |
| PneumoniaInfections and infestations | 0/80 | 1/81 | 0/81 | 1/82 | 1/141 | 3/141 |
| Abdominal herniaGastrointestinal disorders | 1/80 | 0/81 | 0/81 | 0/82 | 0/141 | 0/141 |
| Abdominal painGastrointestinal disorders | 1/80 | 0/81 | 0/81 | 1/82 | 0/141 | 1/141 |
| Fibrous histiocytomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/80 | 0/81 | 0/81 | 0/82 | 0/141 | 0/141 |
| SyncopeNervous system disorders | 1/80 | 0/81 | 0/81 | 0/82 | 0/141 | 0/141 |
| Asthmatic crisisRespiratory, thoracic and mediastinal disorders | 1/80 | 0/81 | 1/81 | 0/82 | 0/141 | 0/141 |
| Umbilical herniaGastrointestinal disorders | 1/80 | 0/81 | 0/81 | 0/82 | 0/141 | 0/141 |
| Event | EOS POS Placebo | EOS POS Benralizumab 2 mg | EOS POS Benralizumab 20 mg | EOS POS Benralizumab 100 mg | EOS NEG Placebo | EOS NEG Benralizumab 100 mg |
|---|---|---|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 30/80 | 28/81 | 24/81 | 26/82 | 42/141 | 42/141 |
| NasopharyngitisInfections and infestations | 8/80 | 11/81 | 7/81 | 13/82 | 5/141 | 13/141 |
| HeadacheNervous system disorders | 8/80 | 8/81 | 6/81 | 9/82 | 8/141 | 13/141 |
| BronchitisInfections and infestations | 3/80 | 8/81 | 6/81 | 3/82 | 13/141 | 9/141 |
| PharyngitisInfections and infestations | 3/80 | 8/81 | 3/81 | 7/82 | 5/141 | 6/141 |
| Rhinitis allergicRespiratory, thoracic and mediastinal disorders | 3/80 | 3/81 | 8/81 | 6/82 | 4/141 | 5/141 |
| Injection site erythemaGeneral disorders | 0/80 | 2/81 | 2/81 | 8/82 | 0/141 | 10/141 |
| InfluenzaInfections and infestations | 4/80 | 3/81 | 7/81 | 6/82 | 10/141 | 6/141 |
| Upper respiratory tractInfections and infestations | 4/80 | 7/81 | 7/81 | 5/82 | 10/141 | 11/141 |
| Injection site painGeneral disorders | 0/80 | 6/81 | 4/81 | 2/82 | 6/141 | 2/141 |
The modified intent-to-treat (mITT) population included all randomized participants who received any dose of investigational product.
| Age, Continuous(years) | Eosinophilic Phenotype (EOS+) Placebo | EOS+ Benralizumab, 2 mg | EOS+ Benralizumab, 20 mg | EOS+ Benralizumab, 100 mg | Non-eosinophil Phenotype (EOS-) Placebo | EOS- Benralizumab, 100 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 45.6 ± 11.7 | 47.1 ± 12.8 | 46.6 ± 13.2 | 47.8 ± 12.9 | 50.0 ± 12.3 | 50.0 ± 11.5 | 48.3 ± 12.4 |
| Sex: Female, Male(Participants) | Eosinophilic Phenotype (EOS+) Placebo | EOS+ Benralizumab, 2 mg | EOS+ Benralizumab, 20 mg | EOS+ Benralizumab, 100 mg | Non-eosinophil Phenotype (EOS-) Placebo | EOS- Benralizumab, 100 mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 53 | 58 | 48 | 60 | 100 | 98 | 417 |
| Male | 27 | 23 | 33 | 22 | 42 | 42 | 189 |
The record gives a start of Dec 2010, a primary completion of Mar 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab